Mehow Innovative Ltd.
美好医疗
301363
Shenzhen Stock Exchange
Company Profile
The company's core competitiveness is primarily reflected in the following aspects: 1. Open R&D Innovation Platform Combining Modular Reuse of Generic Technologies & Vertical Breakthroughs in Specialized Technologies The R&D system integrates both generic and specialized technology platforms. Leveraging technical expertise accumulated through serving global medical device leaders, the R&D team has systematically refined and iterated core competencies including medical component development, precision silicone/plastic molding, and automation technologies. This forms a modularized generic technology platform with cross-domain applicability. Concurrently, the company establishes vertical-specific technology platforms targeting strategic fields like respiratory health, hearing rehabilitation, glucose management, and cardiovascular devices. Through domain-specific knowledge mapping and process decoupling, these platforms deliver customized technical solutions. A dynamic knowledge-sharing mechanism bridges the two platforms, enabling end-to-end technological integration from design to mass production. R&D initiatives are dual-driven by market foresight and client needs. Cross-functional teams conduct preemptive technology research aligned with industry evolution trajectories while building solution matrices for anticipated product upgrades. This proactive model shortens technology conversion cycles by 30-50% and strengthens competitive advantages through early adoption of innovations. The company maintains robust R&D investments, with annual expenditure reaching 141 million yuan in the reporting period (16.75% YoY growth, accounting for 8.82% of revenue). As a national high-tech enterprise and Guangdong manufacturing champion, it holds 263 authorized patents (38 invention patents), 36 software copyrights, 190 trademarks, and 22 medical device certifications. 2. Automated Intelligent Precision Manufacturing System The company has pioneered an automated manufacturing ecosystem featuring self-developed non-standard solutions integrating cutting-edge technologies: Achieves micron-level precision assembly via magnetic levitation systems, zero-clearance rotary actuators, and AI-vision robotics Implements full-process quality monitoring through hermeticity testing, AI vision inspection, and real-time electrical performance validation Developed modular automated production lines with MES integration, enabling digital traceability and 20-35% cost reduction Its world-class mold engineering team masters medical-grade material forming technologies while providing lifecycle services. The integration of online measurement and automated processing ensures both precision and efficiency. Future initiatives will accelerate AI and robotics adoption to reinforce manufacturing leadership. 3. Compliance-Optimized Quality Governance With strict adherence to ISO 13485, FDA, CE, and NMPA standards, the company operates multiple GMP-certified cleanrooms (Class 10K/100K). Recent milestones include: Obtained Class II clinical testing device production authorization Passed NMPA onsite audits for Class III sterile imaging catheters Expanded FDA manufacturing listings for 18 new products Implemented LIMS and CNAS-compliant lab management systems Achieved FDA registration for Malaysia facility and ethylene oxide sterilization certification Having withstood 100+ global regulatory audits, the company serves as drafter of national metrological standards, driving industry quality elevation. 4. Globally Distributed Production Network The strategic multi-site manufacturing model mitigates geopolitical risks while enhancing responsiveness: Malaysia Phase I/II facilities operational; Phase III (2025 completion) to strengthen Asia-Pacific supply chain resilience Chinese bases (Shenzhen, Daya Bay) upgraded with advanced sterilization and testing capabilities Dual-cycle domestic-international capacity synergy supports multinationals' localization needs 5. Premium Client Portfolio The company has earned trust from 10+ global top 100 medical device manufacturers and innovators across: Core sectors: Respiratory devices, cochlear implants, cardiovascular intervention Emerging fields: Surgical robotics, electrophysiology, glucose monitoring (CGM), in-vitro diagnostics Non-medical expansion: Premium consumer health brands leveraging medical-grade manufacturing expertise This client ecosystem validates its technical authority while creating cross-sector innovation spillover effects.
Full description
The company is primarily engaged in the design, development, manufacturing, and sales of medical device precision components and products. It provides global medical device enterprises with end-to-end one-stop services spanning from product R&D to mass production delivery, committed to becoming a world-class medical technology service provider. Closely tracking industry innovation trends, the company adheres to a market-oriented and customer-centric philosophy. It maintains continuous investments in new product development and proprietary technology R&D, achieves breakthroughs in novel technologies and processes, and enhances quality compliance management systems. Leveraging comprehensive advantages in automated intelligent precision manufacturing, the company has established all-round strategic collaborations with multiple global top 100 medical device enterprises and innovative high-tech medical firms across respiratory health, hearing rehabilitation, glucose management, cardiovascular, in-vitro diagnostics, and other specialized fields. 1. Respiratory Health & Hearing Rehabilitation The company maintains long-term strategic partnerships with global leaders in home ventilator and cochlear implant markets. Through sustained R&D investments and close collaboration with client innovation teams, it has achieved continuous breakthroughs in new products, technologies, and manufacturing processes. By integrating proprietary innovations into customer product development cycles, the company solidifies its leadership position in the global home ventilator and cochlear implant CDMO markets. 2. Glucose Management, Cardiovascular & In-Vitro Diagnostics Building dual technological platforms combining universal capabilities (component development, precision molding, automation) with vertical-specific expertise, the company addresses cross-disciplinary technical demands across high-growth sectors. Key milestones include: • Glucose Management: Achieved mass production of automated insulin pen manufacturing lines in 2024. Completed R&D for proprietary "FinePen" series (adjustable disposable pens, pre-filled auto-injectors, energy-storing adjustable pens). Entered delivery phase for CGM components, targeting a $36.5 billion global CGM market by 2030. • Cardiovascular: Established cross-functional teams driving breakthroughs in rhythm management, structural heart devices, and vascular intervention products. • In-Vitro Diagnostics: Developed microfluidic chips, testing consumables, and precision instrument components, with pilot batches under customer validation. 3. MAH Services for Global Medical Leaders As a certified MAH contract manufacturer, the company partners with multinationals like Johnson & Johnson for China-localized production. Leveraging end-to-end service capabilities honed in global high-end markets, it positions itself as a strategic enabler for international brands' supply chain localization under China's "dual circulation" policy. 4. Non-Medical Business Expansion Capitalizing on medical-grade precision manufacturing expertise, the company diversifies into premium consumer sectors including personal care, coffee equipment, fitness products, maternal-infant care, and beauty devices, meeting exacting quality standards of leading lifestyle brands. Future Outlook Centered on medical technology innovation, the company aims to evolve into a globally competitive medical tech solutions provider. By delivering value-added, vertically integrated services spanning design, development, and advanced manufacturing across core therapeutic areas, it seeks to drive transformative growth for clients while establishing multiple value-creation curves in high-potential medical markets.